SCHEMBL190965

SCHEMBL190965

CCOC(=O)c1ccc(Cl)c(Oc2cc(NC(=S)NC(=O)c3ccccc3)ncc2Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.45
P2RY12 Q9H244 2/20 0.45
CYP1A2 P05177 2/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
KMT2A Q03164 3/20 0.44
PKM P14618 2/20 0.44
KCNH2 Q12809 2/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 1/20 0.43
ALOX12 P18054 3/20 0.43
LMNA P02545 2/20 0.43
NPC1 O15118 2/20 0.43
MAPT P10636 2/20 0.42
EPHX1 P07099 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191140 0.87 RAB9A (0.44) RAB9ACYP1A2SMN1; SMN2KMT2APKM
SCHEMBL1330540 0.85 KCNH2 (0.54) RAB9AP2RY12CYP1A2SMN1; SMN2KMT2A
SCHEMBL2659795 0.78 NPC1 (0.51) RAB9ASMN1; SMN2KMT2APKMKCNH2
SCHEMBL2871030 0.77 SMN1; SMN2 (0.57) RAB9AP2RY12CYP1A2SMN1; SMN2KMT2A
SCHEMBL15012132 0.77 NPC1 (0.58) RAB9ACYP1A2SMN1; SMN2KMT2APKM
SCHEMBL190750 0.76 ALDH1A1 (0.42) RAB9ACYP1A2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL190796 0.76 NPC1 (0.49) RAB9ACYP1A2SMN1; SMN2KMT2APKM
SCHEMBL191773 0.75 NPC1 (0.53) RAB9ACYP1A2SMN1; SMN2KMT2APKM
SCHEMBL190809 0.74 GCK (0.62) RAB9ASMN1; SMN2KMT2APKMKCNH2
SCHEMBL190970 0.74 TRPV4 (0.40) RAB9AP2RY12CYP1A2SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 RAB9A 1808/4885P2RY12 4096/4885CYP1A2 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.